ChemoCentryx pulls conditional approval filing by Nick Paul Taylor Thursday, January 24, 2019 The biotech said it withdrew the submission for C5aR antagonist avacopan as it now expects to have the data to file for a full approval next year.
ChemoCentryx eyes combinations after posting pancreatic cancer OS data by Nick Paul Taylor Tuesday, January 23, 2018 Almost 30% of the participants were alive 18 months after starting treatment on a combination of CCX872 and the chemotherapy regimen FOLFIRINOX.
Vifor flies solo, plans spending spree as sister unit files IPO by Nick Paul Taylor Friday, April 7, 2017 Vifor Pharma has become an independent company following the IPO of its sister unit, Galenica Santé.
$85M windfall for PhIII licensing deal sparks a rally for ChemoCentryx by John Carroll Wednesday, May 11, 2016 ChemoCentryx shares shot up 42% on Tuesday as investors sized up the premium $7.50-per-share price Vifor Pharma paid for a stake in the company.
